Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003580 · ClinicalTrials.gov registry record · Phase 2
Amifostine to Treat Side Effects of Treatment in Patients Receiving Radiation Therapy and Cisplatin for Advanced Head and Neck Cancer
A Phase 2 study, sponsored by University of Tennessee.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00003580 is a Phase 2 study that has completed, run by University of Tennessee.
The verdict
NCT00003580, a Phase 2 study, has completed, sponsored by University of Tennessee.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Drugs such as amifostine may protect normal cells from the side effects of chemotherapy and radiation therapy. PURPOSE: Phase II trial to study the effectiveness of amifostine in treating side effects of treatment in patients receiving radiation therapy and cisplatin for advanced head and neck cancer.
Interventions
- DRUG cisplatin
- RADIATION radiation therapy
- DRUG amifostine trihydrate
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-06 |
| Est. Completion | 2004-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003580
The ClinicalTrials.gov registry entry for NCT00003580 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is University of Tennessee, which has 96 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which cisplatin is the first listed.
NCT00003580 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003580 about?
NCT00003580 is a clinical study titled "Amifostine to Treat Side Effects of Treatment in Patients Receiving Radiation Therapy and Cisplatin for Advanced Head and Neck Cancer". RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Drugs such as amifostine may protect normal cells from the side effects of chemotherapy and radiation therapy. PUR...
What is the current status of trial NCT00003580?
This trial is currently completed. It is a Phase 2 study. The study started on 1998-06. Estimated completion is 2004-05.
What interventions are being tested in trial NCT00003580?
The interventions under investigation include: cisplatin (DRUG), radiation therapy (RADIATION), amifostine trihydrate (DRUG).
Who is sponsoring clinical trial NCT00003580?
This trial is sponsored by University of Tennessee, which has 96 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.